ROCKVILLE, Md. and SUZHOU, China, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in three upcoming investor conferences. Oppenheimer 36th Annual H ...

Vancouver, British Columbia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB1; OTC:TEBAF) is pleased to announce further high-grade assay results from the Phase III drill campaign at the Cumavici Ridge polymetallic, epithermal vein zone within its principal Viogor-Zanik project in eastern Bosnia and Herzegovina. Highlights Drillhole CMV25004 intersected 636 g/t Ag Eq. over 4.3 m including: 1,757 g/t Ag Eq over 0.8 m1,319 g/t Ag Eq over 0.4 m ...

Core Insights - BioVie Inc. is hosting a webinar on March 4, 2026, to discuss its investigational drug candidate bezisterim (NE3107) and its orphan drug candidate BIV201 [1][2][3] Group 1: Drug Development - Bezisterim (NE3107) is a first-in-class, orally available small molecule targeting inflammation and insulin resistance, which are key drivers of Alzheimer's, Parkinson's, and Long COVID, showing promising results in improving cognition, motor function, and reducing neuroinflammation [2][6] - BIV201 is a continuous infusion treatment of terlipressin for patients with cirrhosis and ascites, which has received FDA Orphan and Fast Track designations, and is set to enter a Phase 3 trial [3][7] Group 2: Market Potential - BioVie is positioned to create significant value with multiple clinical programs advancing into late-stage development, supported by strong safety data and multi-billion-dollar market opportunities [3] - The company aims to address life-threatening complications in liver disease with no FDA-approved therapies currently available [3][7]

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: TD Cowen 46th Annual Healthcare ConferenceFireside Chat on Monday, March 2 at 1:10 p.m. ET in Boston, MABarclays 28th Annual Global Healthcare ConferenceFireside Chat on Tuesday, March 10 at 10:30 a. ...

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University fo ...

BLFC Sensory Room Image of future sensory Collegium Pharmaceutical Sensory Room for BLFC home matches Scoreboard for BLFC Scoreboard at BLFC Matches at White Stadium with Collegium Branding BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Legacy FC today announced a multi-year partnership with Collegium Pharmaceutical, an emerging biopharmaceutical leader in the Boston area, naming the company an Official Partner of Boston Legacy FC. Through this collaboration, Boston Legacy FC and Collegium are w ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (Nasdaq: MLCI) (“Mount Logan” or the “Company”) today announced that its Board of Directors has authorized a share repurchase program of up to $10 million of the Company’s outstanding common stock through December 31, 2027. The authorization reflects the Company’s continued focus on disciplined capital allocation. It follows the February 2026 completion of its $15 million tender offer, which reduced the Company’s common stock issued and ou ...

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports. The publication reports findings from nine patients who received autologous Natural Killer (NK) cell infus ...

Company Overview - Alignment Healthcare, Inc. is focused on providing high-quality, low-cost care for its Medicare Advantage members, emphasizing a mission-driven approach to senior care [2] - The company utilizes a customized care model, a 24/7 concierge care team, and proprietary technology named AVA to deliver coordinated care [2] - Alignment Healthcare is based in California and partners with nationally recognized local providers to enhance its service offerings [2] Upcoming Events - Alignment Healthcare will present at the Leerink Partners Global Healthcare Conference in Miami, Florida, on March 10, 2026, at 3:40 p.m. EST [1] - A webcast and replay of the presentation will be accessible on Alignment's investor relations website [1]

Core Viewpoint - B2Gold Corp. is undergoing a leadership transition as Clive Johnson retires as President and CEO, with Mike Cinnamond set to succeed him effective June 4, 2026, ensuring continuity in the company's strategic direction [1][3]. Leadership Transition - Clive Johnson has been with B2Gold since its founding in 2007, leading its growth into a significant gold producer with four operating mines producing approximately one million ounces of gold annually [2]. - Johnson will be appointed Chair Emeritus, maintaining his connection with the company and providing support to the Board and management [2]. - Mike Cinnamond, currently Senior Vice President and CFO, will take over as President and CEO, bringing extensive knowledge of the company and experience in financial management and corporate strategy [3][4]. Board Changes - Kelvin Dushnisky transitions from Chair of the Board to Executive Chair, leveraging over 35 years of mining experience to support the new CEO and senior management [5]. - Greg Barnes has been appointed Lead Independent Director, bringing over 35 years of experience in the global mining industry [6]. Future Leadership - Michael McDonald will succeed Cinnamond as CFO effective June 4, 2026, bringing 20 years of experience in finance and corporate development [7][8]. Company Overview - B2Gold is a responsible international senior gold producer headquartered in Vancouver, Canada, with operating mines in Canada, Mali, Namibia, and the Philippines, along with various development and exploration projects globally [9].